Nd:YAG激光联合普萘洛尔治疗颌面部血管瘤的临床疗效观察

Clinical efficacy of Nd:YAG laser combined with propranolol in the treatment of maxillofacial hemangiomas

摘要:

目的 探究Nd:YAG激光联合普萘洛尔治疗颌面部血管瘤的临床疗效。方法 选取2020年5月—2023年5月兴安盟人民医院收治的60例颌面部血管瘤患者，按随机数字表法分为对照组和观察组，各30例。对照组采取Nd:YAG激光治疗，观察组在对照组基础上联合使用普萘洛尔。比较两组治疗效果、血流动力学指标、血管生成因子、瘤体消退程度、不良反应、复发状况。结果 观察组治疗总有效率高于对照组（P <0.05）。观察组治疗前后血流峰值、阻力系数、血管内皮生长因子、碱性成纤维细胞、血管瘤活跃度量表评分的差值均大于对照组（P <0.05）。两组不良反应总发生率比较，差异无统计学意义（P >0.05）。随访2年，观察组复发率低于对照组（P <0.05）。结论 Nd:YAG激光结合普萘洛尔治疗颌面部血管瘤效果显著，可改善血管生成因子、血流动力学指标，促进瘤体消退，复发率较低且安全性良好。

Abstract:

Objective To investigate the clinical efficacy of Nd:YAG laser combined with propranolol in treating maxillofacial hemangiomas.Methods Sixty patients with maxillofacial hemangiomas admitted to Xing'an League People's Hospital between May 2020 and May 2023 were selected and randomly divided into the control group and the observation group (30 patients each) using a random number table. The control group received Nd:YAG laser therapy alone, while the observation group was additionally administered propranolol. Treatment efficacy, hemodynamic parameters, vascular endothelial growth factor (VEGF) levels, degree of tumor regression, adverse reactions, and recurrence rates were compared between groups.Results The overall effective rate of treatment was higher in the observation group compared to the control group (P < 0.05). The differences in peak blood flow, resistance index, levels of VEGF and basic fibroblast growth factor, and hemangioma activity scale scores before and after treatment were greater in the observation group than in the control group (P < 0.05). There was no statistically significant difference in the overall incidence of adverse reactions between the two groups (P > 0.05). After a 2-year follow-up, the recurrence rate was lower in the observation group than in the control group (P < 0.05).Conclusion Combining Nd:YAG laser therapy with propranolol yields significant efficacy in treating maxillofacial hemangiomas. This approach improves VEGF levels and hemodynamic parameters, promotes tumor regression, exhibits a low recurrence rate, and demonstrates a good safety profile.